Oligodendrocyte progenitor cells (OPCs) are present throughout the adult brain and spinal cord and can replace oligodendrocytes lost to injury, aging, or disease. Their differentiation, however, is inhibited by myelin debris, making clearance of this debris an important step for cellular repair following demyelination. In models of peripheral nerve injury, TLR4 activation by lipopolysaccharide (LPS) promotes macrophage phagocytosis of debris. Here we tested whether the novel synthetic TLR4 agonist E6020, a Lipid A mimetic, promotes myelin debris clearance and remyelination in spinal cord white matter following lysolecithin-induced demyelination. In vitro, E6020 induced TLR4-dependent cytokine expression (TNFa, IL1b, IL-6) and NF-jB signaling, albeit at 10-fold reduced potency compared to LPS. Microinjection of E6020 into the intact rat spinal cord gray/white matter border induced macrophage activation, OPC proliferation, and robust oligodendrogenesis, similar to what we described previously using an intraspinal LPS microinjection model. Finally, a single co-injection of E6020 with lysolecithin into spinal cord white matter increased axon sparing, accelerated myelin debris clearance, enhanced Schwann cell infiltration into demyelinated lesions, and increased the number of remyelinated axons. In vitro assays confirmed that direct stimulation of macrophages by E6020 stimulates myelin phagocytosis. These data implicate TLR4 signaling in promoting repair after CNS demyelination, likely by stimulating phagocytic activity of macrophages, sparing axons, recruiting myelinating cells, and promoting remyelination. This work furthers our understanding of immune-myelin interactions and identifies a novel synthetic TLR4 agonist as a potential therapeutic avenue for white matter demyelinating conditions such as spinal cord injury and multiple sclerosis.
debris removal is carried out mainly by macrophages derived from microglia and monocytes, which are the principal phagocytes that remove debris after CNS damage (Br€ uck et al., 1995; Kotter, Zhao, van Rooijen, & Franklin, 2005; Ma et al., 2002; Triarhou & Herndon, 1985; Vallières, Berard, David, & Lacroix, 2006) . Therefore, enhancing or accelerating myelin phagocytosis by macrophages is a promising target to promote oligodendrogenesis and remyelination in the demyelinated CNS.
One strategy to enhance phagocytosis is selective activation of toll-like receptor 4 (TLR4) signaling in microglia and macrophages. For instance, systemic treatment with the TLR4 agonist LPS enhanced CNS macrophage activation and accelerated myelin clearance following spinal cord hemisection (Vallières et al., 2006) . Additionally, mice deficient in TLR4 signaling displayed reduced myelin phagocytosis after peripheral nerve crush, while microinjecting LPS into the lesion of wild-type mice accelerated myelin debris clearance (Boivin et al., 2007) . Previous work from our lab showed that TLR4 activation of macrophages by LPS stimulated myelin debris phagocytosis in vitro (Church, Kigerl, Lerch, Popovich, & McTigue, 2016) and that intraspinal microinjection of LPS in the intact rat spinal cord induced robust OPC proliferation and subsequent formation of new OLs (Schonberg, Popovich, & McTigue, 2007) .
This study builds on previous work showing that TLR4 activation by LPS promotes repair after demyelinating injuries (Glezer, 2006 ).
Here we tested the ability of the novel TLR4 agonist E6020 to accelerate myelin debris clearance and enhance OL replacement after intraspinal demyelination. E6020 (Eisai Inc., Andover, MA) is a well characterized synthetic Lipid A mimetic with a promising preclinical safety profile Morefield, Hawkins, Ishizaka, Kissner, & Ulrich, 2007) . It was developed as a potent nontoxic vaccine adjuvant, in contrast to LPS, which has human toxicity and, since it is a natural product, can have variable potency (Morefield et al., 2007) . E6020 is chemically well defined and activates TLR4 but, unlike LPS, does not activate TLR2/6 (Morefield et al., 2007) . To date, it has not been tested in the CNS. Thus, here we tested its ability to induce OPC proliferation and OL genesis in the adult CNS as well as tested if it could accelerate myelin debris removal and promote remyelination after demyelination. Our new in vitro data show that treating macrophages with E6020 elicits TLR4-dependent cytokine production and activates intracellular nuclear factor-kappa B (NF-jB) signaling. These indices of macrophage activation are similar to those elicited by LPS but require a 10-fold greater concentration to achieve comparable effects. E6020 also significantly enhanced myelin phagocytosis by macrophages in vitro. Intraspinal microinjection of E6020 into the intact rat spinal cord induced macrophage activation, OPC proliferation, and an initial loss of OLs followed by robust OL replacement. Finally, a single intraspinal microinjection of E6020 at the time of lysolecithin-induced demyelination promoted axon sparing, accelerated myelin debris clearance and increased the number of axons myelinated by OLs at 14 days postinjection; surprisingly there was no change OL numbers compared to controls, suggesting that the number of myelin segments per OL was enhanced in the E6020 group. In addition, E6020 treatment significantly enhanced Schwann cell infiltration at day 14 and increased the number of axons remyelinated by Schwann cells 21 days after lysolecithin. This work demonstrates that a single administration of a TLR4 agonist is neuroprotective, boosts macrophage phagocytosis and enhances myelination in the adult CNS, thus highlighting the possibility of manipulating this pattern recognition receptor as a treatment for demyelinating conditions such as spinal cord injury, multiple sclerosis, and other white matter injury or disease.
| M E T H O D S

| E6020
E6020 was developed and generously donated by Eisai, Inc (Andover, MA). It mimics the physiochemical and biological properties of Lipid A moieties in Gram-negative bacteria and activates TLR4 similar to the natural Gram-negative bacteria TLR4 ligand LPS, although the response is attenuated at equimolar doses .
| Bone-Marrow Derived Macrophage Cultures
Bone marrow-derived macrophage cultures were generated as described previously (Longbrake, Lai, Ankeny, & Popovich, 2007 ) from adult female Sprague Dawley rats or TLR4 deficient (C3H/HeJ) or control (C3H/HeOuJ) mice (Jackson Laboratory, Bar Harbor, ME). Briefly, bone marrow derived macrophages (BMDMs) were obtained from bilateral femurs and tibias using aseptic techniques. Marrow cores were flushed into sterile tubes using syringes fit with 26 gauge needles and filled with Dulbecco's Modified Eagle Medium (DMEM)/10% fetal bovine serum (FBS). Cells were triturated 3-5 times, and red blood cells were lysed in lysis buffer (0.15 M NH 4 Cl, 10 mM KHCO 3 , and 0.1 mM Na 2 EDTA, pH 7.4). Cells were washed once in media then plated and cultured in DMEM supplemented with 0.5% gentamicin, 1% glutamax, 1% HEPES, 0.001% b-mercaptoethanol, 10% FBS, and 20% supernatant from sL929 cells. The sL929 (which contains macrophage colonystimulating factor) is needed to promote differentiation of bone marrow cells into macrophages (7-10 days) (Burgess et al., 1985) . Cells were replated at 2 million cells per well on day 7 in DMEM media supplemented with 10% FBS, 1% glutamax, and 0.5% gentamicin.
In the first experiment, rat cells were treated with replating media with or without LPS (0.1 lg/mL; Sigma-Aldrich) or E6020 (0.001, 0.01, 0.1, 1, 10, or 100 lg/mL; Eisai) for 24 h. In a second experiment, rat cells were treated with myelin and replating media or E6020 (1 lg/mL) for 2, 4, or 24 hr (see methods below). Mouse TLR4 deficient or control analysis for highly similar sequences against known sequence databases. Briefly, total RNA was purified from each well (3 wells/treatment) using Trizol and quantified by spectrophotometry. cDNA was prepared from RNA by reverse transcription with SuperScript II and random primers (Invitrogen). PCR reactions were carried out using 10 ng of cDNA, 500 nmol/L of each primer, and SYBR Green master mix (Applied Biosystems, Foster City, CA) in 10 lL reactions. Levels of PCR product were measured using SYBR Green fluorescence collected during Real-Time PCR on an Applied Biosystems 7900 system. Standard curves were generated for each gene using a control cDNA dilution series to check primer efficiency. Melting point analyses were performed for each reaction to confirm single amplified products. Data were calculated using the DDC t method (Schmittgen & Livak, 2008) and expressed as fold change from media treated cells (gene/18s ratio for uninjured samples equals one). Forward and reverse primer sequences for each gene are listed in Table 1 .
| RAW-Blue Cells
RAW-Blue cells (InvivoGen) that had been passaged 12 times and stored in liquid nitrogen were thawed and grown in DMEM media supplemented with 10% FBS, 1% glutamax, and 0.5% gentamicin. Cells were passaged 23 and grown to >80% confluence. Cells were treated with LPS (10, 100, 1000 ng/mL; Sigma-Aldrich, St. Louis, MO) or E6020 (0.001, 0.01, 0.1, 1, 10, or 100 lg/mL; Eisai) made in heatinactivated FBS containing DMEM media for 24 hr, following which NF-jB/activator protein-1 (AP-1) activation was assessed using QUANTI-Blue according to manufacturer's instructions (InvivoGen, San Diego, CA). All treatment groups were run in triplicate.
| Myelin Isolation & pHrodo Red Dye Labeling
Myelin from the brain of an adult female Sprague Dawley rat was isolated using a modified version of the methods outlined in (Hendrickx, Schuurman, van Draanen, Hamann, & Huitinga, 2014) . The whole brain was mechanically dissociated through a 70 lm mesh filter using cold 0.1 M PBS followed by density gradient separation using Percoll (Sigma; GE17-0891-01) of 70, 35, and 0% Percoll in PBS. Myelin was collected from the 0-35% interface, resuspended in 0.32 M sucrose, and further purified using a sucrose gradient (Norton & Poduslo, 1973) of 0.85, 0.32, and 0 M sucrose. Liquid was aspirated and myelin was washed in dH 2 O and suspended in 0.1 M PBS pH 7.4.
Myelin concentration was measured using the Pierce BCA protein assay kit (ThermoFisher Scientific, 23225) and labeled with pHsensitive dye pHrodo red, succinimidyl ester (ThermoFisher Scientific, P36600) dissolved in dimethyl sulfoxide (DMSO). Myelin was suspended in 0.1 M PBS pH 8.4 and incubated with 0.1 mM dye at room temperature for 45 min. Myelin 1 dye was spun and resuspended in 0.1 M PBS pH 7.4 and stored at 2808C until used.
| Phalloidin Immunofluorescence
BMDM morphology was visualized using Phalloidin staining with Hoechst nuclear stain. Fixed cells were washed in 5%FBS/PBS, permeablized with 0.2%Triton X-100, and incubated with Alexa Fluor Phalloidin 488 (1:1000, ThermoFisher Scientific, A12379) for 3 hr at room temperature. Cells were washed and treated with Hoechst (1:50,000) for 5 min and left in PBS. Images were obtained at 203 magnification using the Thermo Scientific ArrayScan XTI.
| Myelin Phagocytosis Analysis of BMDMs
Cells were identified as BMDMs if they were Hoechst and Phalloidin positive. Phalloidin positive BMDMs were determined by thresholding against the background intensity in nonstained wells. The average Phalloidin intensity was at least 3 times the background intensity. Hoechst positive cells that were Phalloidin negative were excluded from analysis. BMDM myelin uptake was determined by thresholding the myelin intensity against the background intensity in nontreated BMDM wells.
A BMDM that had taken up myelin was at least 3 times the maximum background intensity in the nontreated wells. The presence of myelin was quantified using the ArrayScanXTI Spot Detector Algorithm (ThermoFisher). 250 Hoechst/Phalloidin1 cells were analyzed per well for their myelin content. The percentage of cells containing myelin was determined for BMDMs that received either media or E6020 (1 lg/mL) treatment for 2, 4, or 24 hr. Three or four wells per treatment were analyzed and averaged.
| Microinjections
Adult female Sprague Dawley rats (250 g) were anesthetized with ketamine (80 mg/kg i.p.) and xylazine (10 mg/kg i.p.). A laminectomy was performed at the T8 vertebral level using aseptic technique. A glass micropipette (custom pulled and beveled to an external tip diameter of 30-40 lm) was inserted 0.7 mm lateral to midline and 1.1 mm ventral to the surface of the exposed cord. A pneumatic picopump (DKI, Tujunga, CA) was used to inject 500 nL of E6020 (10 mg/mL; SigmaAldrich) or vehicle (0.1 M PBS) (n 5 4/group) into rats randomly assigned to treatment groups. After injection, the micropipette remained in place for 3 min to prevent backflow; the micropipette was then slowly removed, and the injection site was marked with sterile charcoal (Sigma-Aldrich). The musculature surrounding the laminectomy was sutured, the skin was closed with wound clips, and each rat was given 5 mL of saline before being placed in warmed recovery cages.
| Lysolecithin
A laminectomy at T8 vertebral level was performed as described above.
A double-barreled micropipette (custom made and beveled to a total external tip diameter of 60 lm) was inserted 0.9 mm lateral to midline and 1.1 mm ventral to the surface of the exposed cord to target lateral white matter. A pneumatic picopump was used to inject 500 nL of lysolecithin (1%; L-a-Lysophosphatidylcholine from egg yolk 99%;
Sigma-Aldrich) through one pipette tip then 500 nL of E6020 (10 mg/ mL) or vehicle (0.1 M PBS) through the second pipette tip; rats were randomly assigned to the E6020 or vehicle groups. After the second injection, the micropipette remained in place for 3 min to prevent backflow; the micropipette was then slowly removed, and the injection site was marked with sterile charcoal (Sigma-Aldrich). The musculature surrounding the laminectomy was sutured, the skin was closed with wound clips, and each rat was given 5 mL of saline before being placed in warmed recovery cages.
| BrdU
To label proliferating cells, the thymidine analog 5-bromo-2 0 -deoxyuridine (BrdU; 50 mg/kg in sterile saline; Sigma-Aldrich) was injected intraperitoneally (i.p.) 1, 2, and 4 hr after surgery in animals surviving 1 day, or 1 hr after surgery and once a day up to 7 days until sacrifice in animals surviving 7 days for microinjection studies.
| Tissue Processing
Naïve rats were sacrificed at 1 or 7 days after microinjection of PBS or E6020 (n 5 3-4/group). Rats receiving lysolecithin and PBS or E6020 co-injection were sacrificed at 3, 7, 14, or 21 days (n 5 4-5/group). All rats were anesthetized with a lethal cocktail of ketamine/xylazine Serial cross-sections (10 lm) were cut through each block using a Microm cryostat (HM 505 E) then were collected on SuperFrost Plus slides (Fisher Scientific, Fair Lawn, NJ) and stored at 2208C.
Additional rats microinjected with lysolecithin and PBS or E6020
(n 5 5/group) were perfused 14 days after injection with PBS followed by 4% paraformaldehyde/2% gluteraldehyde solution. Spinal cords were removed, and 1 mm segments of tissue at the injection site and rostral and caudal were blocked. Tissue was processed for Epon embedding and semithin sections cut at 1 lm in a transverse orientation on an ultramicrotome (Ultracut MZ6, Leica Microsystems, Austria).
Sections were stained with 1% toluidine blue, dipped in histoclear, and coverslipped.
| Immunohistochemistry
Microinjection sites were identified as the section with greatest CD11b immunoreactivity. In most cases needle tracts were evident with CD11b immunoreactivity. Lysolecithin demyelination lesion epicenters were determined as the area with the greatest demyelination determined with eriochrome cyanine (EC)/neurofilament (NF)
immunostaining.
For tissue analysis, the following targets were visualized using 
| Proportional Area Analysis
To obtain activated microglia/macrophage density, images were digitized and manually outlined using image analysis software (MCID Elite, Imaging Research Inc., Canada). For the initial microinjection study, the entire ipsilateral half was quantified; in lysolecithin treated tissue analysis was confined to the lesioned area (determined by EC/NF). The proportional area of activated macrophages was calculated by dividing the area immunoreactive for CD11b by the scan area. Areas of missing tissue were excluded from this and all analyses.
For lysolecithin treated rats, intraspinal lipid accumulation was analyzed using the proportional area of oil red O staining normalized to the lesion scan area outlined using EC/NF staining. The trace of core lesion area outlined was overlaid on oil red O stained cross-sections, and positive staining was analyzed within that region.
| Cell Density Quantification
Cells immunoreactive for NG21/BrdU1, CC11/GFAP2, and p751
were manually counted at 403. The criteria to count single-labeled or double-labeled cells included each profile having a well-defined border surrounding an identifiable nucleus. A cell was only counted if both criteria were met in the same plane of focus. Cell type was verified at higher power (643) Macrophages respond to the TLR4 ligand LPS with cytokine production and activation of NF-jB. Here we sought to identify a concentration of the synthetic TLR4 agonist E6020 that produced a similar response in BMDMs to a commonly used dose of LPS (0.1 lg/mL) in vitro. Rat
BMDMs were treated for 24 hr with DMEM media, LPS, or E6020 then inflammatory gene expression was analyzed using rtPCR. shows morphology of BMDMs counterstained with Hoescht (blue) treated with media (e), LPS (0.1 lg/mL) (f), or E6020 (1 lg/mL) (g) for 24 hr. LPS and E6020 induced a larger more rounded cell body typical of an activated macrophage, compared to the small rounded or bipolar morphology in the media-treated group. *p < .05 vs. LPS; 1 p < .05, 11 p < .01 versus media (a-c). Scale bar 5 100 lm (e-g). Data are mean-6 SEM. [Color figure can be viewed at wileyonlinelibrary.com] that, although less potent than LPS, E6020 activates macrophages, mimicking effects of TLR4 activation previously described using blood mononuclear cells . Here, the reduced potency of E6020 versus LPS at the same concentration supports previous findings of reduced cytokine expression with equimolar doses of E6020 and LPS . Verification that E6020 works specifically through TLR4 was obtained using mouse macrophages deficient in TLR4 signaling. This revealed that while E6020 induced TNFa, IL-1b, and IL-6 mRNA in wild type mouse macrophages as expected, macrophages lacking TLR4 signaling were completely unresponsive to E6020 (and LPS; data not shown).
E6020 is reported to activate NF-jB . To confirm this response in our hands, RAW-Blue Cells were treated with DMEM media, or varying concentrations of LPS or E6020 for 24 hr. This macrophage reporter cell line secretes an embryonic alkaline phosphatase inducible by NF-jB that can be measured using QUANTI-Blue medium. As expected, LPS treatment significantly increased NF-jB activation compared to media. E6020 treatment also significantly increased NF-jB activation, again with 10-fold less potency than LPS (Figure 1d ).
Phalloidin staining of activated macrophages revealed an obvious morphological transformation in LPS-and E6020-activated macrophages. At rest, unstimulated macrophages displayed bright phalloidin immunoreactivity with compact round or bipolar morphology ( Figure   1e ). LPS and E6020 both induced an activated morphology, with the majority of macrophages displaying large, round cell bodies 24h after treatment (Figure 1f,g ). Taken together, these data verify that E6020 activates TLR4 on macrophages in vitro, enhancing their ability to produce NF-jB-regulated cytokines.
| E6020 Microinjection Activates Macrophages in the Intact Spinal Cord
Previous work showed that microinjection of the TLR4 agonist LPS into the rat spinal cord white matter/gray matter border induces macrophage activation, especially within the gray matter (Schonberg et al., 2007) . We tested whether microinjecting E6020 also activates macrophages in vivo.
Microinjection of E6020 (1 lg/mL) at the white matter/gray matter border activated intraspinal macrophages. At day 1 postinjection, small rounded macrophages were present throughout the ipsilateral gray and white matter, with the majority of cells concentrated in an ellipse in the lateral white matter (Figure 2a ). The area occupied by activated macrophages increased by 7 days, most notably in the white matter, in contrast to vehicle-injected cords which displayed no macrophage activation at either time (Figure 2b , c). Quantification of CD11b immunoreactivity verified that macrophage activation increased significantly between 1 and 7 day after intraspinal E6020 microinjection (Figure 2d ). Double-labeling with Iba1 confirmed the macrophage phenotype of the CD11b1 cells (data not shown).
| OPCs Proliferate and New OLs Are Formed in E6020 Injection Sites
Intraspinal LPS injection into the intact adult rat spinal cord induces OPC proliferation around the injection site by day 3 and subsequent OL genesis by day 7 (Schonberg et al., 2007; Schonberg & McTigue, 2009 ). Here we tested whether E6020 had a similar effect. Proliferating OPCs (BrdU1/NG21), OL numbers (CC11), and new OLs (BrdU1/CC11) were counted ipsilateral to the microinjection sites.
Few OPCs incorporated BrdU at any time in vehicle-treated cords (Figure 3a,b) . In contrast, E6020 significantly increased OPC proliferation over 7 days (Figure 3a,c) . BrdU1 NG2 cells were present throughout the ipsilateral spinal cord, with most concentrated in the lateral white matter surrounding the area of greatest macrophage activation. TLR4 activation of microglia by LPS can induce OL death in mixed glial cultures and after intracerebral injection (Jeong, Ji, Kim, Jou, & Joe, 2013; Lehnardt et al., 2002; Zhang, Yao, Whetsell, & Sriram, 2013) .
Our laboratory has also noted significant OL loss 1 day after intraspinal LPS injection (personal observation) followed by robust OL genesis and increased OL numbers 1 week later in adult rats (Schonberg et al., 2007) . To determine if E6020 affects OL loss or replacement, spinal cords were examined at day 1 and day 7 postinjection (Figure 4a ,b).
Vehicle injections had no effect on OLs at either time (Figure 4a ,c).
E6020 microinjection significantly reduced OL numbers by day 1 postinjection, most notably in the region of robust macrophage activation (Figure 4c ; it should be noted as well that on occasion E6020 caused robust macrophage activation in gray matter, which was associated with neuron loss in addition to OL loss at day 1). However, by day 7, OL number in E6020-injected tissue had increased >6-fold, resulting in 40% more OLs compared to controls (Figure 4b,c) . To verify that this response was due to new OL formation, BrdU1/CC11 cells were quantified at day 7. Compared to controls, E6020-treated spinal cords had significantly more new OLs in the gray matter and white matter (Figure 4d ). Collectively, these data demonstrate that intraspinal TLR4 activation by E6020 induced an initial loss of OLs, followed by robust OPC proliferation and widespread OL genesis.
| E6020 Does Not Increase Lesion Size following Lysolecithin-Induced Demyelination
Next, the ability of TLR4 activation via E6020 to enhance remyelination in the CNS was tested. For this, lysolecithin was injected into the intact rat spinal cord, which induces transient demyelination followed by spontaneous remyelination within 5 weeks (Hall, 1972; Blakemore, 1976) . Macrophage depletion impairs remyelination after intraspinal lysolecithin (Kotter, Setzu, Sim, van Rooijen, & Franklin, 2001) , revealing an essential role for macrophages in myelin repair. However, given that TLR4 activation causes acute OL loss, it is possible that activating TLR4 concomitant with lysolecithin would exacerbate lesion formation and alter repair. To examine this, lysolecithin was co-injected with vehicle or E6020 into the intact spinal white matter in adult rats. The area of demyelination was quantified based on myelin (EC) and axon (neurofilament) double-labeling at 3-21 days postinjection. At all times examined, the demyelinated area in E6020-treated tissue was comparable to controls ( Figure 5a,b,g ), revealing that TLR4 activation at the time of demyelination did not enhance lesion size. 
| TLR4 Activation with E6020 Accelerates Macrophage Activation after Demyelination
Data above show that E6020 microinjection induces rapid and robust macrophage activation (see Figure 2) . Thus, next we assessed if E6020 treatment increased macrophage activation over that induced by lysolecithin in demyelinated lesions. Injection of lysolecithin plus vehicle or E6020 both elicited macrophage activation in the lesions; macrophages were distributed throughout the demyelinated zone at day 3 and formed dense clusters by 7-14 days after injection (Figure 5c,d) . However, E6020 accelerated the macrophage response, as these sections contained significantly more macrophage immunoreactivity at day 7 compared to controls, which had not changed from day 3 (Figure 5h ). Macrophage reactivity robustly increased in control tissue between 7 and 14 days, at which time lesions co-injected with vehicle had significantly more macrophage reactivity compared to E6020 (Figure 5h ). Double labeling of CD11b and Iba1 confirmed these cells were macrophages (data not shown).
| E6020 Accelerates Myelin Debris Clearance in Demyelination Lesions
Data from various injury models implicate TLR4 activation in promoting myelin debris clearance from demyelinated regions (Boivin et al., 2007; Li, Zhang, Zhang, Wen, Lu, & Shen, 2014; Vallières et al., 2006) . Here, the ability of E6020 to accelerate or enhance myelin debris phagocytosis in the demyelinated lesions was tested. Oil red O (ORO) stain was used to label phagocytosed myelin debris (Ma et al., 2002) .
After lysolecithin plus vehicle injection, few ORO1 lipid droplets were present in phagocytic cells at 3-7 days; these increased significantly by 14-21 days postinjection in the control cords ( Figure   5e ,i), which closely matches the time course of macrophage activation in this group. ORO labeling in E6020 treated tissue was similar to vehicle at day 3 but was significantly increased by day 7 (Figure   5f ,i). This high level of lipid debris was eliminated by 14 and 21 days postinjection, resulting in ORO levels significantly lower than that in the lysolecithin plus vehicle group (Figure 5f ,i). These data demonstrate that TLR4 activation via E6020 robustly accelerates myelin debris phagocytosis and degradation following lysolecithin-induced demyelination.
To verify that E6020 directly stimulates myelin phagocytosis by macrophages, rat BMDMs were co-stimulated in vitro with myelin and media or E6020 for 2, 4, or 24 h. Myelin was tagged with pHrodo red, a dye that fluoresces in acidic environments, such as macrophage lysosomes. Using this technique, the number of macrophages containing FIG URE 4 Oligodendrocytes are lost and replaced following E6020 microinjection (MI). Representative images of oligodendrocytes (CC1, brown) and astrocytes (GFAP, gray) counterstained with methyl green at the injection site at 7 days after vehicle (a) and E6020 MI (b). Arrowheads indicate CC11 oligodendrocytes. Red box over spinal cord schematics outline where representative images were taken. (c) Quantification of CC11 oligodendrocytes in the ipsilateral half showed oligodendrocyte loss 1 day after E6020 MI (striped bars) compared to vehicle (black bars), and a rebound in oligodendrocyte numbers slightly beyond baseline at 7 days. (d) BrdU1 oligodendrocytes were counted in the gray and white matter at the injection site 7 days post-MI from animals receiving BrdU at 1 hr and 1-7 days. In both gray and white matter regions, the E6020 group (striped bars) had significantly more new oligodendrocytes compared to vehicle (black bars). **p < .01, ***p < .001 versus vehicle. Scale bar 5 100 lm (a, b). Data are mean 6 SEM. [Color figure can be viewed at wileyonlinelibrary.com] CHURCH ET AL. | 891 phagocytosed myelin was quantified. In myelin plus vehicle-treated BMDMs, 13% had phagocytosed myelin by 2 hr, which rose to 25% at 4 hr and slightly declined by 24 hr (Figure 6a,b) . Treatment with E6020 significantly increased the number of myelin-containing macrophages at 2 and 24 hr, compared to controls (Figure 6a) . Indeed, almost 50% of macrophages treated with E6020 had taken up myelin by 2 hr (47%, Figure 6a ,c), which increased further by 24 hr when over 70% of TLR4-activated macrophages had phagocytosed myelin (Figure   6a ,c). Similar to above (Figure 1) , E6020 treatment induced a larger, rounded morphology by 24 hr (Figure 6d ). These data provide evidence that TLR4 activation directly enhances myelin debris uptake by macrophages and suggests a potential mechanism of E6020-mediated acceleration of myelin debris clearance from the intraspinal demyelinated lesions.
| E6020 Increased Axon Survival after Lysolecithin and Enhanced OL Remyelination but Not OL Formation
Lysolecithin is a demyelinating detergent that typically causes minimal direct damage to axons (Hall & Gregson, 1971; Hall, 1972) .
Remyelination of bare axons may begin as early as day 7 in rodents with near complete remyelination by 3-5 weeks (Blakemore, 1976; Jeffery & Blakemore, 1995) . Because E6020 treatment accelerated myelin debris phagocytosis, we hypothesized that remyelination also would occur earlier. In semithin plastic sections prepared 14 days after injection of lysolecithin plus E6020 or vehicle, sample boxes were used to quantify bare and thinly myelinated axons indicative of OL remyelination. Unexpectedly, lesion cores were mostly shows that E6020 accelerates myelin debris clearance. Oil red O is significantly greater at day 7 after E6020 treatment (f') compared to vehicle (e') and is cleared from the lesion by day 14 (f") at the time when staining is the highest with vehicle (e"). Quantification of (g) lesion size (EC/NF), (h) macrophage activation (CD11b), and (i) myelin debris clearance (oil red O stain) at 3, 7, 14, and 21 days post-lysolecithin plus vehicle (black bars) or E6020 (striped bars) co-injection. *p < .05, **p < .01, ***p < .001 versus vehicle. Scale bars 5 100 lm (a, b), 50 lm (c-f). Data are mean 6 SEM. [Color figure can be viewed at wileyonlinelibrary.com] void of axons and instead were filled with macrophages in both groups (Figure 7a,b) . Therefore, axon counts were restricted to just within lesion borders where both groups contained axons. As To determine if the greater number of remyelinated axons in E6020 lesions correlated with an increase in OLs, the number of OLs within lysolecithin lesions was counted at 14 and 21 days postinjection.
Interestingly, OL numbers were comparable in both groups at each time (Figure 8a-c) , revealing that although there was more OL remyelination at day 14, E6020 did not alter the timing or extent of OL replacement after lysolecithin.
| TLR4 Activation via E6020 Increased Schwann Cell Recruitment and Myelin Production in Intraspinal Demyelination Lesions
Upon inspection of the 14 day epon-embedded sections, it was clear that many bare axons had a one-to-one association with cells resembling Schwann cells. Indeed, it has been known for over 30 years that Schwann cells contribute to remyelination in the CNS following chemical demyelination (Blakemore, 1976; Blakemore, Eames, Smith, & McDonald, 1977; Graça & Blakemore, 1986) . To examine Schwann cell infiltration into the lesions, 14 day postinjection sections were 
| DISCUSSION
This work demonstrates that E6020, a synthetic Lipid A mimetic and TLR4-specific agonist, enhances macrophage phagocytosis and accelerates repair after intraspinal demyelination. In vitro, E6020 treatment of macrophages induced cytokine production, intracellular NF-jB signaling, and a round "activated" morphology. In comparison to LPS, E6020 was less potent, as expected, but still produced the same general activated phenotype . For LPS to activate and signal through TLR4, additional co-stimulatory molecules are required, including LPS binding protein (LBP), lymphocyte antigen 96 (MD2), and cluster of differentiation 14 (CD14) (Lu et al., 2008) . E6020, however, does not require CD14 and whether MD2 is necessary for its activation of TLR4 signaling is unknown .
Recently, the importance of CD14 in conferring and heightening LPS sensitivity and regulating inflammatory function in microglia was reported (Janova et al., 2015) . Perhaps lack of CD14 involvement in E6020 activation of TLR4 contributes to its decreased potency. The elevated inflammatory response of macrophages to increasing doses of E6020 demonstrates a wide range of sensitivity to this TLR4 agonist, and thus the potential to finely tune macrophage function in vitro and in vivo.
Previously, our group showed that intraspinal LPS injection activates macrophages and enhances OPC proliferation and OL genesis (Schonberg et al., 2007) . Here we show that intraspinal E6020 injection produces similar effects. Interestingly, despite the fact that injections of both LPS and E6020 were made into the gray/white matter border, there were subtle but important differences in the magnitude and location of the macrophage reaction. With both TLR4 agonists, cells with round activated morphology were present throughout the ipsilateral cord; however, macrophage activation was greatest in the lateral white matter after E6020 microinjection whereas LPS caused focal activation of dense macrophage clusters in gray matter. Because E6020 does not contain the saccharide scaffold of LPS and other synthetic TLR4 agonists , its lipophilic nature may preferentially allow it to accumulate in the white matter. Thus, comparable injections of LPS, which cause the greatest macrophage response in the gray matter (Schonberg et al., 2007) , create focal zones of dense macrophage activation with significant neuron loss (Jeong et al., 2013) . E6020 did not cause neuron loss, except in the occasional injections that elicited a small but robust macrophage response in gray matter. Thus, differences in the diffusion characteristics of these TLR4 agonists may create focal zones of activated macrophages with more/less neurotoxic potential.
Alternatively, differences in accessory molecules involved in TLR4 signaling between LPS and E6020 (discussed above) may alter the migration or phenotype of activated macrophages to preferentially accumulate near neuron cell bodies and areas of dense vasculature or white matter tracts, respectively. For example, CD14 (required for LPS but not E6020 signaling via TLR4) enhanced macrophage recruitment and infiltration in an abdominal aortic aneurysm induction model (Blomkalns et al., 2013) . Furthermore, dopamine increases CD141 monocyte adherence and migration within the brain (Coley, Calderon, Gaskill, Eugenin, & Berman, 2015) , and dopaminergic projections within the spinal cord terminate in gray matter (Lindvall, Bj€ orklund, & Skagerberg, 1983) . Therefore, in addition to diffusion properties, TLR4 cosignaling molecules may determine the magnitude and localization of LPS versus E6020 mediated macrophage activation within the spinal cord. E6020 microinjection into the uninjured spinal cord caused acute OL loss, followed by OPC proliferation and OL genesis over 7 days, primarily around the area of greatest macrophage activation. In vitro work shows LPS activated microglia are toxic to OL lineage cells (Pang, Cai, & Rhodes, 2000; Lehnardt et al., 2002; Pang et al., 2010) , potentially through release of cytokines or reactive oxygen/nitrogen species.
While this may explain the acute OL loss after E6020/TLR4 activation in the otherwise naïve spinal cord, it is still unclear what initiates the subsequent oligodendrogenic response. It is likely not due to the presence of bare axons, as we showed previously that intraspinal TLR4 activation with LPS induces only minimal demyelination (Schonberg et al., 2007) , although others have detected greater demyelination after a larger volume of LPS microinjected into spinal cord white matter (Felts et al., 2005) . E6020 may induce pro-oligogenic growth factor expression in microglia directly or via crosstalk with astrocytes, as we detected elevated IL-1b and ciliary neurotrophic factor (CNTF) following intraspinal LPS injection (Schonberg et al., 2007) , and others have noted an LPS-induced rise in TGFb, LIF, IL-6, and the antiinflammatory factor oncostatin M in the CNS (Glezer & Rivest, 2010; Jeong et al., 2013) . The preferential white matter targeting of E6020-mediated macrophage activation and OL genesis may increase the therapeutic value of this agonist for boosting repair after white matter injuries in which OLs have been lost.
To examine the potential for E6020 to promote white matter repair, its ability to enhance remyelination after lysolecithin demyelination was tested. Importantly, E6020-induced TLR4 activation did not expand the area of demyelination, despite work by others showing LPS may cause prominent demyelination (Felts et al., 2005) . Both lysolecithin and intraspinal TLR4 activation can cause edema, blood-brain barrier permeability and oligodendrocyte loss (Hall, 1972 Blakemore et al., 1977; Felts et al., 2005; Schonberg et al., 2007; Tourdias et al., 2011) . However, when E6020 and lysolecithin were coinjected, OL number and edema were not different from that caused by lysolecithin alone, showing that TLR4 activation via E6020 did not exacerbate tissue pathology.
The differences in timing of macrophage activation and debris phagocytosis in lysolecithin lesions between E6020 and control groups may suggest a differential effect of E6020 in resident microglia versus peripherally derived macrophages. One would assume microglia were exposed to E6020 almost immediately after injection, yet microglial/ macrophage activation was comparable in E6020 and control groups 3 days after injection. Peripheral monocytes infiltrate lysolecithin lesions within 48 hr (Imai et al., 2008) and the earliest ones may have been activated by E6020 as its half-life is up to 40 hr . Between day 3 and day 7, macrophage activation and myelin debris phagocytosis significantly increased in E6020 cords but did not change in saline-treated lysolecithin cords, suggesting activation of monocyte-derived macrophages may have been greater in the E6020 group compared to saline. Interestingly, although macrophage activation was delayed in the saline plus lysolecithin group, the saline group displayed significantly greater peak macrophage activation compared to the E6020 group at day 14, which may have been due to prolonged exposure to myelin debris (Clarner et al., 2012; Wang et al., 2015) . Thus, TLR4 agonism by E6020 accelerated yet tempered macrophage activation after chemical demyelination.
In vitro data in this study showed that E6020 directly stimulates myelin debris uptake by macrophages. Similarly, our results show E6020 enhances macrophage myelin debris uptake in vivo, and promotes complete removal of lipid debris at 14-21 days after lysolecithin.
In contrast, lipid debris remained significantly elevated in vehicletreated lysolecithin lesions through day 21. Recently, we showed that LPS also stimulates myelin uptake by cultured macrophages, and that TLR4 deficient mice have impaired myelin clearance after spinal cord injury . Central and peripheral nerve injury models have also illustrated the essential role of TLR4 signaling in clearing myelin debris (Boivin et al., 2007; Vallières et al., 2006) . Notably, LPS treatment increases neutral lipid uptake by cultured human macrophages, revealing a conserved role for TLR4 signaling in this process (Napolitano, Sennato, Botham, Bordi, & Bravo, 2013) . TLR4 activation of macrophages induces phagocytic programming through MyD88 and IRAK4/p38 signaling (Doyle et al., 2004) . Although not assessed in this work, future studies should determine if E6020 uses a similar mechanism to induce phagocytosis. The greater than 3 day delay in phagocytosis of lipid debris relative to drug treatment is interesting since E6020 likely would have been eliminated by 3 day postinjection. Since myelin debris clearance was comparable between groups at 3 day postinjection, E6020 must have induced an early change in microglia and macrophage function that was not evident until after 3 days.
Here we show for the first time that addition of a TLR4 agonist to a CNS demyelinating lesion preserved axons and likely enhanced the amount of remyelination per OL. TLR4 signaling in macrophages has been shown to promote axonal regeneration after nerve injury both in vitro and in vivo through enhancing phagocytosis of growth inhibitory debris (Boivin et al., 2007; David & Lacroix, 2003; Rajbhandari et al., 2014) . Furthermore, TLR4 mediated microglial clearance of a-synuclein is essential for limiting neurodegeneration and neuron loss in a model of multiple system atrophy (Stefanova et al., 2011) . Here axon loss following chemical induced demyelination was significantly reduced by E6020. These data suggest that in addition to TLR4-mediated actions promoting axon regeneration, TLR4 signaling in macrophages also creates an environment that is protective to demyelinated CNS axons.
While it has been appreciated for several years that myelin debris inhibits differentiation of OPCs into OLs, these data suggest that it may also impair the ability of OLs to extend new myelin sheaths, since E6020 and control lesions had comparable OL numbers but the E6020 group had significantly more OL-derived remyelinated axons. It is also possible that TLR4 activation concomitant with demyelination altered the macrophage response (e.g., different growth factor expression) that in turn enhanced the ability of new OLs to extend myelinating processes.
Interestingly, although E6020 microinjection into the intact spinal cord induced oligodendrogenesis, E6020 co-injection with lysolecithininduced demyelination did not alter overall OL numbers during recovery. Comparable lesion development and chronic OL numbers after lysolecithin between E6020 treated tissue and controls indicate similar OL loss and replacement in both groups. Thus the robust oligogenic effect of E6020 in the uninjured CNS is diminished in the more complex demyelinated environment.
Our data also show TLR4 activation increased Schwann cell infiltration and remyelination in the demyelinated lesions. For decades it has been thought the astrocytic glial limitans restricts Schwann cell entry from the PNS, and their entry into the CNS occurs through compromising the glial limitans or more specifically the astrocytic processes at the dorsal root entry zone or along blood vessels, particularly in ventral and gray matter areas (Blakemore & Patterson, 1975; Franklin & Blakemore, 1993; Raine, Traugott, & Stone, 1978; Sims, Durgun, & Gilmore, 1998) . Astrocytes can inhibit Schwann cell migration by disrupting integrin signaling (Afshari, Kwok, White, & Fawcett, 2010) , so perhaps intraspinal TLR4 activation alters astrocytes in a way that is more permissive to Schwann cell infiltration. An intriguing alternative possible source for the Schwann cells is from intraspinal progenitors.
Recent work suggests CNS resident OPCs can differentiate into
Schwann cells after a demyelinating injury (Talbott et al., 2006; Zawadzka et al., 2010) and that astrocytes play a major role in determining the balance of OPC-derived OLs vs. Schwann cells (Talbott et al., 2005; Monteiro de Castro, Deja, Ma, Zhao, & Franklin, 2015) .
Thus, E6020 in our study may have either recruited peripheral Schwann cells into the spinal cord and/or pushed resident OPCs toward a Schwann cell fate, with the collective outcome being increased intraspinal Schwann cell numbers and enhancement of their contribution to remyelination. Neuregulin 1 is a key regulator of Schwann cell migration, proliferation, and survival (Heermann & Schwab, 2013) . Recently, systemic TLR4 activation was shown to alter neuregulin 1 expression in the brain (Yang et al., 2016) , thus it is possible that TLR4 activation in the CNS can influence Schwann cell recruitment via neuregulin signaling. Our recent data implicate TLR4 signaling in regulating growth factor and cytokine expression in the damaged spinal cord , therefore it is likely that E6020 treatment altered the inflammatory environment after lysolecithin demyelination to favor Schwann cell recruitment and survival. An alternative possibility is that the increased number of axons within the E6020 demyelinated lesions indirectly mediated the effects on Schwann cell infiltration and myelination. While lysolecithin is not typically toxic to axons when used in the concentration used here, for an unknown reason it did kill many axons in the center of the lesions.
However, this serendipitously revealed that E6020 co-injected with lysolecithin reduced axon loss. Schwann cells are known to express TLR4 and release MCP-1 (CCL2) in response to damaged nerve, contributing to macrophage accumulation and Wallerian degeneration (Karanth, Yang, Yeh, & Richardson, 2006) . In addition to injected E6020, putative endogenous TLR4 ligands are likely present in lysolecithin demyelination lesions similar to after spinal cord injury (Kigerl & Popovich, 2009 ). Thus, activation of TLR4 on recruited Schwann cells could have contributed to the accelerated accumulation of macrophages in E6020 co-injected tissue, which can infiltrate the CNS within one week of lysolecithin demyelination (Blakemore et al., 1977) .
In sum, this report illustrates the importance of TLR4 signaling in promoting myelin repair, which can be achieved using a novel synthetic agonist. Specifically, E6020 accelerated myelin debris phagocytosis by macrophages, enhanced axon sparing and promoted OL and Schwann cell remyelination. Since macrophage clearance of debris is impaired with aging and contributes to decreased remyelination after CNS demyelinating injuries (Natrajan et al., 2015; Ruckh et al., 2012) , data in this report indicate that selective activation of inflammation could be used to boost repair after injury and potentially enhance immune cell function in the aged CNS (for review, see Goldstein, Church, Hesp, Popovich, & McTigue, 2016) . This work also sheds light on a signaling mechanism that may be involved in remyelination of central axons by peripheral myelinating cells. Lastly, these results highlight that acutely activating a single inflammatory-related receptor after demyelination can have long-term effects that alter the function of multiple cell types and change the reparative processes in the damaged adult CNS.
